Drugmaker GSK to collaborate with CEPI in effort to develop coronavirus vaccine
Share:
(Reuters) - British drugmaker GlaxoSmithKline Plc is collaborating with the Coalition for Epidemic Preparedness Innovations (CEPI) to contribute towards the effort of developing a vaccine for the coronavirus outbreak, GSK and CEPI said on Monday.GSK will make its "adjuvant platform technology" available for developing a vaccine against the 2019-nCoV virus, according to the statement.The use of adjuvant allows for production of more vaccine doses and hence would increase availability to more..